Braveheart Bio, Inc. (BRVE) insider trading.
In Q3 2026, insiders at Braveheart Bio, Inc. reported 19 non-derivative transactions on 29 Forms 3, 4 and 5: 13 open-market purchases worth $159.0M and 0 sales.
- Transactions
- 19
- Purchases (P)
- 13
- Sales (S)
- 0
- Net shares, P minus S
- 8,835,275
- Insiders
- 11
- Last filed
- 2026-08-11
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Forbion Growth Opportunities Fund III Cooperatief U.A. / Forbion Growth III Management B.V. / Forbion Ventures Fund VII Cooperatief U.A. / Forbion Ventures VII Management B.V. | TenPercentOwner | 4 | 2 | 0 |
| OrbiMed Genesis GP LLC / OrbiMed Capital GP IX LLC / ORBIMED ADVISORS LLC | Director, TenPercentOwner | 3 | 2 | 0 |
| Chimovits Erez | Director, TenPercentOwner | 3 | 2 | 0 |
| Andreessen Marc L / HOROWITZ BENJAMIN A / AH Equity Partners Bio IV, L.L.C. / AH Bio Fund IV, L.P. | TenPercentOwner | 2 | 1 | 0 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | TenPercentOwner | 1 | 0 | 0 |
| Lubner David Charles | Director | 1 | 1 | 0 |
| Murdoch Travis | Director, Officer · CEO and President | 1 | 1 | 0 |
| Anderson Michele A. | Officer · Chief Development Officer | 1 | 1 | 0 |
| Malek David I | Director | 1 | 1 | 0 |
| Viehbacher Christopher | Director | 1 | 1 | 0 |
| Rickey James Paul | Officer · Chief Financial Officer | 1 | 1 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-07 | OrbiMed Genesis GP LLC / OrbiMed Capital GP IX LLC / ORBIMED ADVISORS LLC | P (A) | 1,666,667 | $18 | 11,901,826 | Form 4 |
| 2026-08-07 | OrbiMed Genesis GP LLC / OrbiMed Capital GP IX LLC / ORBIMED ADVISORS LLC | C (A) | 9,132,420 | — | 10,235,159 | Form 4 |
| 2026-08-07 | OrbiMed Genesis GP LLC / OrbiMed Capital GP IX LLC / ORBIMED ADVISORS LLC | P (A) | 273,333 | $18 | 273,333 | Form 4 |
| 2026-08-07 | Chimovits Erez | C (A) | 9,132,420 | — | 10,235,159 | Form 4 |
| 2026-08-07 | Chimovits Erez | P (A) | 1,666,667 | $18 | 11,901,826 | Form 4 |
| 2026-08-07 | Chimovits Erez | P (A) | 273,333 | $18 | 273,333 | Form 4 |
| 2026-08-07 | Andreessen Marc L / HOROWITZ BENJAMIN A / AH Equity Partners Bio IV, L.L.C. / AH Bio Fund IV, L.P. | P (A) | 1,100,000 | $18 | 10,232,420 | Form 4 |
| 2026-08-07 | Andreessen Marc L / HOROWITZ BENJAMIN A / AH Equity Partners Bio IV, L.L.C. / AH Bio Fund IV, L.P. | C (A) | 9,132,420 | — | 9,132,420 | Form 4 |
| 2026-08-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | C (A) | 7,420,091 | — | 7,420,091 | Form 4 |
| 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. / Forbion Growth III Management B.V. / Forbion Ventures Fund VII Cooperatief U.A. / Forbion Ventures VII Management B.V. | C (A) | 9,132,420 | $0 | 9,720,546 | Form 4 |
| 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. / Forbion Growth III Management B.V. / Forbion Ventures Fund VII Cooperatief U.A. / Forbion Ventures VII Management B.V. | P (A) | 1,680,000 | $18 | 10,185,478 | Form 4 |
| 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. / Forbion Growth III Management B.V. / Forbion Ventures Fund VII Cooperatief U.A. / Forbion Ventures VII Management B.V. | P (A) | 1,920,000 | $18 | 11,640,546 | Form 4 |
| 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. / Forbion Growth III Management B.V. / Forbion Ventures Fund VII Cooperatief U.A. / Forbion Ventures VII Management B.V. | C (A) | 7,990,867 | $0 | 8,505,478 | Form 4 |
| 2026-08-07 | Lubner David Charles | P (A) | 55,555 | $18 | 55,555 | Form 4 |
| 2026-08-07 | Murdoch Travis | P (A) | 83,333 | $18 | 2,940,670 | Form 4 |
| 2026-08-07 | Anderson Michele A. | P (A) | 1,111 | $18 | 332,161 | Form 4 |
| 2026-08-07 | Malek David I | P (A) | 4,166 | $18 | 533,845 | Form 4 |
| 2026-08-07 | Viehbacher Christopher | P (A) | 83,333 | $18 | 609,519 | Form 4 |
| 2026-08-07 | Rickey James Paul | P (A) | 27,777 | $18 | 520,927 | Form 4 |
Transaction codes in this quarter
Get BRVE insider transactions through the API
Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=2131524&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · BRVE company page · Braveheart Bio, Inc. on SEC.gov
Questions
Are insiders buying or selling Braveheart Bio, Inc. (BRVE)?
In Q3 2026, insiders at Braveheart Bio, Inc. reported 19 non-derivative transactions on 29 Forms 3, 4 and 5: 13 open-market purchases worth $159.0M and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Braveheart Bio, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.
Plain-text version for agents and LLMs: /insider-trading/brve.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.